The Supreme Court of the Russian Federation confirmed on June 4, 2024 that the patent on the drug Forxiga (INN dapagliflozin) held by AstraZeneca was granted and extended in accordance with the law and is valid until May 15, 2028.
The Supreme Court decision also confirms the groundlessness of the objections to patent number 2746132.
It was noted that AstraZeneca’s original Forxiga drug was produced in a facility in the Kaluga region of Russia, within the scope of a special investment agreement signed by AstraZeneca with the Ministry of Industry and Trade of the Russian Federation and the Kaluga region. The plant increases production volumes every year and fully meets the growing needs of the Russian healthcare system.
It was previously reported that Astra Zeneca received RF patent number 2337916 for the production of a drug called dapagliflozin (trade name Forxiga), which is not internationally registered, in May 2003. It gave the company the sole right to manufacture the drug until May 15, 2023. The company also received a new patent number 2746132 for the same active ingredient, with patent validity until 2028.
What are you thinking?
Source: Gazeta
Ben Stock is a business analyst and writer for “Social Bites”. He offers insightful articles on the latest business news and developments, providing readers with a comprehensive understanding of the business world.